Authorized distributor • Original products from Korea • Support in Polish, Russian, English, German and Czech
PL RU EN DE CZ
0
← All products
AFIRA Tirzepatide 40 mg (Lyophilized Powder)
Afira Biosystems

AFIRA Tirzepatide 40 mg (Lyophilized Powder)

Tirzepatide 40 mg lyophilized powder for solution for injection

For order — message us on Telegram
Message on Telegram (@obotax_shop)

In stock — dispatch within 48h

❄️ Temperature-controlled delivery (2–8°C) across the EU.

GLP-1 / GIP Dual Agonist Once-Weekly Subcutaneous Pharmaceutical Grade

Overview

AFIRA Tirzepatide 40 mg offers ultra-pure lyophilized peptide in a sealed vial. The 40 mg configuration provides practitioners with full flexibility over diluent volume and final reconstituted concentration for personalized patient regimens.

Strictly for certified healthcare practitioners and clinical facilities

Dual Incretin Mechanism: GLP-1 + GIP Agonism

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By simultaneously activating both incretin pathways, it exerts synergistic metabolic control: promoting glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriate glucagon release, slowing gastric motility, and stimulating central hypothalamic satiety circuits to curb appetite and enhance peripheral insulin sensitivity.

Dual Incretin Mechanism of Action (GLP-1 & GIP Synergy)
Dual Incretin Mechanism of Action • Synergistic GLP-1 & GIP receptor activation across brain, pancreas, stomach, and adipose tissue.

Administration

Reconstitute with 2 mL bacteriostatic water or 0.9% sterile saline. Slow injection down vial wall, gentle swirl without shaking.

AFIRA Tirzepatide 40 mg (Lyophilized Powder)
Step-by-step sterile reconstitution protocol for lyophilized Tirzepatide with cold-chain maintenance (2°C - 8°C).

Clinical Dose Titration & Escalation Protocol

To ensure gastrointestinal tolerability, Tirzepatide administration must follow a stepwise escalation protocol. Treatment initiates at a low starting dose of 2.5 mg subcutaneously once weekly for the initial 4 weeks (adaptation phase). The dose is then increased to 5.0 mg once weekly. Subsequent increments of 2.5 mg may occur at minimum 4-week intervals based on clinical assessment and tolerance, up to the maximum dose of 15.0 mg weekly.

Clinical Titration and Escalation Schedule
Standard Once-Weekly Subcutaneous Escalation Schedule • Minimum 4-week adaptation periods between dose tiers.

Technical & Pharmaceutical Specifications

AFIRA Tirzepatide 40 mg (Lyophilized Powder) Specifications
Peptide purity > 99.0%
Content 40 mg Tirzepatide
Vial type Vacuum-sealed sterile injection vial
Brand Afira Biosystems
Powder storage 2°C – 8°C (up to 24 months)

Storage Requirements & Cold Chain Management

Store refrigerated at 2°C to 8°C (36°F to 46°F). Protect from direct light. Do not freeze. For pre-filled pens: once in use, the pen may be kept at room temperature (below 30°C / 86°F) for up to 21-28 days. For reconstituted vials: maintain in refrigerator at 2°C to 8°C and use sterile single-use syringes.

FAQ

How much diluent should be added to the 40 mg vial?

Adding 2.0 mL of solvent provides an intuitive concentration of 20 mg/mL (0.125 mL = 2.5 mg; 0.25 mL = 5.0 mg).